Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6127
Revised: August 2, 2013
Accepted: August 8, 2013
Published online: October 7, 2013
Core tip: Recent advances in treatment modalities have improved the survival rate of patients with hepatocellular carcinoma (HCC). However, long-term outcomes of patients with HCC remain unsatisfactory because of the high incidence of distant intrahepatic recurrence, multicentric recurrence and low survival rates. In particular, hepatitis C virus-related hepatocellular carcinoma has a much higher recurrence rate than other cancers. In this article, we describe the prognosis of recurrent HCC and the therapeutic strategies for reducing recurrent HCC.